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Thiazolidinediones enhance vascular endothelial
growth factor expression and induce cell growth











Background: It is known that thiazolidinediones are involved in regulating the expression of various genes,
including the vascular endothelial growth factor (VEGF) gene via peroxisome proliferator-activated receptor g
(PPARg); VEGF is a prognostic biomarker for non-small-cell lung cancer (NSCLC).
Methods: In this study, we investigated the effects of troglitazone and ciglitazone on the mRNA expression of
VEGF and its receptors in human NSCLC cell lines, RERF-LC-AI, SK-MES-1, PC-14, and A549. These mRNA expressions
were evaluated by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis. We also
studied the effect of Je-11, a VEGF inhibitor, on the growth of these cells.
Results: In NSCLC cells, thiazolidinediones increased the mRNA expression of VEGF and neuropilin-1, but not that
of other receptors such as fms-like tyrosine kinase and kinase insert domain receptor-1. Furthermore, the PPARg
antagonist GW9662 completely reversed this thiazolidinedione-induced increase in VEGF expression. Furthermore,
the addition of VEGF inhibitors into the culture medium resulted in the reversal of thiazolidinedione-induced
growth inhibition.
Conclusions: Our results indicated that thiazolidinediones enhance VEGF and neuropilin-1 expression and induce
the inhibition of cell growth. We propose the existence of a pathway for arresting cell growth that involves the
interaction of thiazolidinedione-induced VEGF and neuropilin-1 in NSCLC.
Background
Peroxisome proliferator-activated receptor g (PPARg)
belongs to a family of ligand-activated transcription fac-
tors. PPARg is an intracellular sensor for fatty acids and
fatty acid derivatives, which in turn act as endogenous
ligands for PPARg. PPARg and its ligand activators regu-
late several lipid and glucose metabolism pathways [1].
In humans, PPARg is expressed in multiple tissues,
including the breast, colon, prostate, lung, placenta, and
pituitary tissues [2-5]. PPARg activation is antiprolifera-
tive by virtue of its differentiation-promoting effects. For
example, ligands activating PPARg were effective in
arresting the growth of dedifferentiated tumor cells in
multiple tumor types [2,4-9], and they promoted
differentiation of tumor cells and inhibited spontaneous
metastasis in a xenograft model [7]. However, the
mechanism by which PPARg arrests growth has not
been completely clarified.
PPARg is a molecular target for thiazolidinediones
(TZDs), a class of insulin-sensitizing agents, such as tro-
glitazone, ciglitazone, pioglitazone, and rosiglitazone. It
is known that TZDs are involved in regulating the
expression of various genes, including the genes encod-
ing vascular endothelial growth factor (VEGF) and its
receptors. VEGF (also called VEGF-A) is one of the
most potent angiogenic factors, playing a key role in the
physiological regulation of endothelial cell growth. It has
been reported that rosiglitazone represses VEGF expres-
s i o nv i aaP P A R g-responsive element in the VEGF gene
promoter [10] and that pioglitazone reduces VEGF
expression [11]. On the other hand, there are several
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increase VEGF expression [12-19]. This difference in
results may be because of the different cell type used in
the study. But it is unclear whether these conflicting
results are because of any mechanism.
Currently, lung cancer is the most frequent cause of
cancer-related deaths in the developed world, and the
chief histological type (affecting about 80% of lung can-
cer patients) is non-small-cell lung cancer (NSCLC).
With the advent of partially effective but potentially
toxic adjuvant chemotherapy, it has become important
to find biomarkers for identifying patients with the high-
est likelihood of recurrence, and who will benefit most
from the adjuvant chemotherapy. In the past several
decades, many papers have reported molecular markers
or proteins that may have prognostic significance in
NSCLC. One such study reported that increased VEGF
expression has consistently been shown to affect
NSCLC outcome [20]. Thus, VEGF is thought to be a
molecular marker and therapeutic target in managing
NSCLC.
Although TZDs arrest cell growth, including the
growth of NSCLC cells, the relationship between its
anti-tumor effect of and the regulation of VEGF expres-
sion is unknown. Therefore, the aim of this study was to
investigate whether TZDs up- or down-regulate the
expression of VEGF-A and its receptors in NSCLC and
whether these VEGF-receptor interactions influence cell
growth.
Methods
Human NSCLC cell lines
Lung squamous cell carcinoma line RERF-LC-AI, lung
adenocarcinoma cell lines PC-14 and A549 were
obtained from the RIKEN BioResource Center, Ibaraki,
Japan. Lung squamous cell c a r c i n o m al i n eS K - M E S - 1
was purchased from DS Pharma Biomedical, Osaka,
Japan. The RERF-LC-AI cells were cultured in a Minimal
Essential Medium (MEM) (Sigma-Aldrich, St. Louis, MO,
USA) supplemented with 10% fetal bovine serum (Invi-
trogen, Carlsbad, CA, USA). The SK-MES-1 cells were
cultured in MEM containing 10% fetal bovine serum and
1% non-essential amino acids (Invitrogen, Carlsbad, CA,
USA). The PC-14 cells were cultured in RPMI1640 med-
ium (Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum. The A549 cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitro-
gen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum. The cells were incubated at 37°C in a
humidified atmosphere of 5% CO2 in air.
Chemicals
Troglitazone was kindly provided by Daiichi Sankyo
(Tokyo, Japan). Ciglitazone, GW9662, Je-11, and JNK
Inhibitor II were purchased from Calbiochem (La Jolla,
CA, USA); U0126 was purchased from Promega (Madi-
son, WI, USA); and SB 202190 from Sigma-Aldrich (St.
Louis, MO, USA). These chemicals were dissolved in
dimethyl sulfoxide (DMSO) with a final concentration
of 0.1% DMSO in the culture medium.
Quantitative real-time RT-PCR analysis
Total RNA was extracted from the RERF-LC-AI, SK-
MES-1, PC-14, or A549 cells by using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). Complementary DNA
was synthesized using 0.1 μg of total RNA and random
primers, with the RETROscript kit (Ambion, Austin,
TX, USA). Quantitative real-time RT-PCR analysis was
performed using the Applied Biosystems 7300 Real-
Time PCR System and the TaqMan Gene Expression
Master Mix, according to the manufacturer’s specifica-
tions (Applied Biosystems, Foster City, CA, USA). Taq-
Man probes for human VEGF-A (Hs00173626_m1),
KDR (Hs00176676_m1), Flt-1 (Hs00176573_m1), NRP-1
(Hs00826129_m1), hypoxia-inducible factor 1a (HIF-1a)
(Hs00153153_m1), and PPARg coactivator-1a (PGC-1a)
(Hs00173304_m1) were also purchased from Applied
Biosystems. To normalize the relative expression of the
genes of interest, eukaryotic 18S rRNA (Hs99999901_s1,
X03205.1) was used as an endogenous control. All
experiments were performed in triplicate.
Western blot analysis
The protein extracts (5 μg) obtained from the PC-14 cells
were separated using 5-20% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). After elec-
trophoresis, the proteins were transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore,
Bedford, MA, USA) and blocked overnight in BlockAce
(Dainippon Sumitomo Pharma, Osaka, Japan) at 4°C. The
proteins were then reacted with primary polyclonal anti-
bodies against human b-actin (#4967; Cell Signaling
Technology, Beverly, MA, USA), VEGF (ab46154;
Abcam, Cambridge, UK), Phospho-MAPK Family (#9910;
Cell Signaling Technology), or MAPK Family (#9926;
Cell Signaling Technology) at 4°C overnight, washed with
Tris Buffered Saline Tween (TBST), reacted with second-
ary polyclonal antibodies against rabbit IgG (Chemicon
International, Temecula, CA, USA) for 1 h, and washed
again with TBST. After being reacted with horseradish
peroxidase-conjugated anti-rabbit IgG, the immune com-
plexes were visualized using ECL Plus detection reagents
(GE Healthcare, Waukesha, WI, USA) and the Lumines-
cent Image Analyzer LAS-3000 (Fujifilm, Tokyo, Japan).
Cell growth assay
The cell number was determined by performing the
WST-1 assay using the Cell Counting Kit (Dojindo,
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Briefly, 100 μl of the PC-14 cells, at a concentration of
8×1 0
4 cells/ml were seeded on a 96-well cell culture
plate (Corning, Corning, NY, USA). After 24 h, each well
was incubated with various concentrations of troglitazone
and Je-11 for 0, 24, or 48 h. After each incubation period,
cell growth was determined using the Cell Counting Kit
and a model 680 microplate reader (Bio-Rad Labora-
tories, Richmond, CA, USA) at a wavelength of 405 nm.
Statistical analysis
Data are expressed as mean (SD). Statistical analysis was
performed either by one-way analysis of variance and
subsequent Tukey multiple comparison procedure, or by
two-way analysis of variance with subsequent Bonferroni
post-test; all of these were performed using the Graph-
Pad Prism Software (version 4). P < 0.05 was considered
statistically significant.
Results
First, we determined whether troglitazone affects the
expression of VEGF-A and its receptors, fms-like tyro-
sine kinase (FLT-1/VEGFR1), kinase insert domain
receptor 1 (KDR/VEGFR2), and neuropilin-1 (NRP-1) in
the human lung cancer cell lines, RERF-LC-AI, SK-
MES-1, PC-14, and A549 (Table 1). In these cell lines,
we found that troglitazone had a dose-dependent effect
on the expression of VEGF-A mRNA. To further prove
that troglitazone enhances VEGF-A expression in lung
cancer cells, we studied the effects of ciglitazone on the
expression of VEGF-A mRNA in the RERF-LC-AI and
PC-14 cells. Ciglitazone enhanced the expression of
VEGF-A mRNA in both cell lines; however, it was less
effective than troglitazone (Figure 1). The mRNA
expression of its receptors, KDR and FLT-1, was hardly
affected; however, mRNA expression of NRP-1, which is
thought to be a receptor of the VEGF-A splicing variant
VEGF165 [21], was affected in a dose-dependent man-
ner. In addition, the level of FLT-1 and KDR mRNA
expression in the all cell lines were extremely low
(threshold cycle values of these mRNAs were around
34-37 cycles; data not shown), or not detected (N.D.).
We also investigated the mRNA expression of transcrip-
tion factor HIF-1a, a known regulating factor of VEGF-
A [22,23], and transcriptional coactivator PGC-1a
(Table 1). Our results indicate that troglitazone signifi-
cantly enhanced HIF-1a expression in the RERF-LC-AI,
SK-MES-1, and PC-14 cells (Table 1). On the other
hand, the expressions of PGC-1a mRNA in the RERF-
LC-AI and SK-MES-1 cells were not affected by troglita-
zone, and PGC-1a mRNA in the PC-14 cells was not
detected. These results indicate that, in NSCLC, troglita-
zone enhances VEGF-A mRNA expression by increasing
HIF-1a expression, and that the VEGF-A receptor is
mainly NRP-1. We hypothesize that the interactions of
VEGF-A and NRP-1 directly affect cell growth, because
the arrest of cell growth by TZDs has been widely
reported.
Table 1 Relative mRNA expression levels of VEGF-A, its receptors, transcription factor HIF-1a, and transcriptional
coactivator PGC-1a.
Troglitazone (μM) VEGF-A FLT-1 KDR NRP-1 HIF-1a PGC-1a
RERF-LC-AI (Squamous cell carcinoma) DMSO 1.00 ± 0.28 1.00 ± 0.13 N.D. 1.00 ± 0.03 1.00 ± 0.16 1.00 ± 0.20
10 1.14 ± 0.08 1.08 ± 0.43 1.00 ± 0.18 1.24 ± 0.31 0.95 ± 0.20
50 1.39 ± 0.42 0.97 ± 0.48 1.03 ± 0.45 1.27 ± 0.23 0.82 ± 0.05
100 4.26 ± 0.74 ** 1.23 ± 0.18 5.79 ± 0.48*** 1.35 ± 0.26 0.92 ± 0.10
SK-MES-1 (Squamous cell carcinoma) DMSO 1.00 ± 0.06 N.D. 1.00 ± 0.24 1.00 ± 0.04 1.00 ± 0.23 1.00 ± 0.41
10 1.21 ± 0.17 1.29 ± 0.26 1.09 ± 0.11 1.40 ± 0.66 1.00 ± 0.26
50 1.81 ± 0.18** 0.60 ± 0.05 1.07 ± 0.04 3.07 ± 0.32*** 1.09 ± 0.22
100 3.34 ± 0.16*** 0.49 ± 0.15* 1.42 ± 0.06*** 3.13 ± 0.11*** 0.85 ± 0.06
PC-14 (Adenocarcinoma) DMSO 1.00 ± 0.07 N.D. N.D. 1.00 ± 0.05 1.00 ± 0.05 N.D.
10 1.13 ± 0.12 0.98 ± 0.11 1.29 ± 0.09**
50 1.80 ± 0.08 1.29 ± 0.47 1.39 ± 0.08**
100 4.18 ± 0.21*** 1.68 ± 0.24* 1.35 ± 0.09**
A549 (Adenocarcinoma) DMSO 1.00 ± 0.05 N.D. N.D. 1.00 ± 0.12 1.00 ± 0.23 1.00 ± 0.10
10 1.06 ± 0.11 0.89 ± 0.05 1.40 ± 0.66 1.16 ± 0.28
50 1.90 ± 0.32*** 1.35 ± 0.42 3.07 ± 0.32*** 1.95 ± 0.44**
100 2.10 ± 0.16*** 1.04 ± 0.12 3.13 ± 0.11*** 1.36 ± 0.06
Data were normalized relative to the level of 18S rRNA, and expressed as mean (SD) of 3 experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle control.
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VEGF-A and its receptor NRP-1, and cell growth inhibi-
tion by troglitazone, PC-14 cells were used for the fol-
lowing experiment. Because the expressions of FLT-1
and KDR mRNA were not detected in the PC-14 cells.
Western blot analysis showed that VEGF-A protein
levels varied with TZD levels in a dose-dependent man-
ner (Figure 2A). The results were consistent with those
obtained by RT-PCR analysis. GW9662, a PPARg
antagonist, completely blocked the TZD-induced expres-
sion of VEGF-A mRNA through a PPARg-dependent
pathway in the PC-14 cells (Figure 2B). These results
indicate that the TZDs–troglitazone and ciglitazone–
induce the expression of VEGF-A mRNA and protein
and that this induction depends on PPARg activation.
We investigated the effects of VEGF-A on cell growth
by using the VEGF inhibitor Je-11. Je-11 directly binds
to VEGF and acts as an inhibitor of VEGF-stimulated
autophosphorylation [24]. It was found that 0.5 μMo f
Je-11 had a marginal effect, whereas 1.0 μM had serious
effects on cell growth (Figure 3A). Thus, we investigated
whether Je-11 affects troglitazone-induced VEGF-A-
mediated cell growth arrest (Figure 3B, C). Interestingly,
we found that 1.0 μM of troglitazone could not arrest
cell growth in the presence of 0.5 μM Je-11. Although
there have been no reports suggesting that the binding
of VEGF-A and Je-11 causes inhibition of VEGF-A
(VEGF165) and NRP-1, our result suggests that the
growth inhibition of the PC-14 cells by troglitazone
depends on VEGF-A and its receptors in these cells.
Mitogen-activated protein kinases (MAPKs) are key
participants in cell proliferation, survival, and differen-
tiation. Hence, we investigated the role of MAPKs in
the mechanism by which troglitazone induces the
Figure 1 Effect of TZDs on VEGF-A mRNA expression in lung cancer cell lines. RERF-LC-AI (left panel) and PC-14 (right panel) cells were
treated with 0, 10, 50, or 100 μM of troglitazone (upper panel) or ciglitazone (lower panel). The culture medium contained 0.1% DMSO to
maintain the same conditions throughout the experiments. After 24 h of treatment, specific mRNA was quantified using real-time PCR. Data
were normalized relative to the level of 18S rRNA, and expressed as mean (SD) (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle control.
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composed of 3 distinct protein kinases MEK-ERK1/2,
p38, and c-Jun N-terminal kinase (JNK). To clarify
whether the signaling of each MAPK is involved in the
enhancement of VEGF-A expression by troglitazone, we
examined the effects of the inhibitors of MEK (U0126),
p38 (SB 202190), and JNK (JNK Inhibitor II). We found
that enhanced VEGF-A expression was required for the
inhibition of JNK phosphorylation and that VEGF-A
enhancement was slightly arrested when using the MEK
inhibitor U0126 and the p38 inhibitor SB 202190 com-
pared to vehicle control (Figure 4). Additionally, Figure
5 indicates that phosphorylated-JNK levels were clearly
reduced in PC-14 cells treated with troglitazone,
whereas other phosphorylated- and non-phosphorylated
MAPKs remained at the same level. These results
indicate that troglitazone-induced VEGF-A expression is
negatively regulated by the JNK signaling pathway.
Discussion
In this study, we showed that TZDs increase the mRNA
expression of VEGF-A and NRP-1 but not that of FLT-
1 and KDR in NSCLC cells. We also showed that
GW9662, a PPARg antagonist, completely reverted the
TZD-induced expression of VEGF-A mRNA to the ori-
ginal level and that this was accompanied by the expres-
sion of transcriptional factor HIF-1a.V E G F - A
expression has been reported to be regulated by tran-
scription factor HIF-1a [22,23]. Recently, it has been
reported that the transcriptional coactivator PGC-1a
regulates VEGF expression by an HIF-1a independent
pathway [25]. Our results indicate that troglitazone
Figure 2 The expression of VEGF-A protein and PPARg dependent pathway. A. PC-14 cells were treated with 0, 10, 50, or 100 μM
troglitazone or ciglitazone and 48 h after treatment the expression of VEGF-A protein was measured by western blot analysis. B. PC-14 cells
were treated with or without GW9662 (20 μM), a PPARg inhibitor, for 1 h before they were exposed to troglitazone or ciglitazone (50 μM each).
After 24 h of thiazolidinedione treatment, the relative expression of VEGF-A mRNA was evaluated using real-time PCR. Data are expressed as
mean (SD) (n = 3). ***P < 0.001 vs. vehicle control.
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either 0, 0.5, or 1.0 μM Je-11 and cell numbers were determined after 0, 24, and 48 h. PC-14 cells were treated with either 0, 0.1, 1.0, 10, or 50
μM troglitazone containing either 0 μM Je-11 (B) or 0.5 μM Je-11 (C) and cell numbers were determined 24 h and 48 h after treatment. Data are
expressed as mean (SD) (n = 6). ***P < 0.001 vs. vehicle control.
Figure 4 Effect of the MAPK inhibitors on the expression of VEGF-A mRNA. PC-14 cells were treated with 10 μM of each inhibitor for MEK
(U0126), p38 (SB 202190), and JNK (JNK Inhibitor II), and specific mRNA was quantified 0, 6, 12, 24, and 48 h after treatment by using real-time
PCR. Data were normalized relative to the level of 18S rRNA and expressed as mean (SD) (n = 3). *P < 0.05, ***P < 0.001 vs. vehicle control.
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dependent manner.
Western blot analysis showed that the level of VEGF-
A proteins also increased in the presence of TZDs.
Therefore, we also studied the effect of the VEGF inhi-
bitor Je-11. Recently, it has been reported that anti-
VEGF monoclonal antibodies significantly arrest cell
growth in SK-MES-1, a squamous cell carcinoma cell
line from the lung [26]. However, an interesting finding
of our study was that the inhibition of VEGF by Je-11
partially blocked the troglitazone-induced growth inhibi-
tion in NSCLC cells, whereas FLT-1 and KDR are still
present albeit in very small amounts. Because NRP-1
binds only to the VEGF-A isoform VEGF165 [22], these
results suggest that growth is arrested by the interaction
of VEGF165 and NRP-1. In addition, our results showed
that troglitazone reduces phosphorylated-JNK levels and
inhibiting the phosphorylation of JNK is necessary for
inducing the expression of VEGF-A mRNA. Similarly, it
has been reported that TZD inhibits the proliferation of
human NSCLC NCI-H23 cells and that these effects are
associated with ERK1/2 activation and SAPK/JNK deac-
tivation [27]. Although we did not detect ERK1/2 activa-
tion, JNK deactivation was observed at 24 h after TZD
treatment (Figure 5). These differences might be attribu-
ted to the concentration of TZD and the type of cell
line. Further, JNK inhibitors upregulated the expression
of VEGF mRNA at all time points after treatment, but
MEK inhibitor and p38 inhibitor did not affect the
expression of VEGF-A mRNA at 24 h after treatment,
as compared to the expression in the vehicle control.
Taken together, these results indicate that TZD-induced
VEGF-A expression is negatively regulated mainly by
the JNK pathway.
VEGF is a major angiogenic factor that stimulates the
proliferation and migration of endothelial cells. Four
VEGF isoforms composed of 121, 165, 189, and 206
amino acids can be synthesized by alternative splicing of
VEGF mRNA. The larger isoforms (VEGF189 and
VEGF206) are cell-associated and bind to glycosamino-
glycans, whereas the smaller isoforms (VEGF121 and
VEGF165) are secreted into the extracellular matrix [23].
Recently, it was reported that VEGF189 is the major
VEGF-A isoform present in NSCLC cells, and the expres-
s i o no fV E G F 1 8 9m R N A ,i nN S C L Cc e l l s ,w a s5t o1 0
times higher than that of VEGF165 mRNA [28].
VEGF165 is mainly secreted, whereas VEGF189 is cell-
associated and is almost completely sequestered in the
extracellular matrix [23]. These VEGF isoforms probably
have different functions in cancer tissues. Although sev-
eral types of tumor cells express VEGF-A and its recep-
tors, the VEGF-A receptor neuropilin-1 (NRP-1) is only
expressed in the pancreatic carcinoma cell lines Panc-1
and MIA PaCa-2 [29]. Because NRP-1 only binds to
VEGF165, one of the several isoforms of VEGF-A [21], it
is possible that the binding of VEGF165 to NRP-1 causes
cell progression in these pancreatic carcinoma cells.
Furthermore, the results of studies on VEGF inhibition
using Je-11 suggested that VEGF enhances cell prolifera-
tion (Figure 3A). However, the inhibition of VEGF by Je-
11 partially relieved the TZD-induced cells from growth
arrest. Therefore, we believe that TZD treatment cause
the growth arrest of NSCLC cells by the mechanism con-
taining VEGF-A (VEGF165) and NRP-1 interaction.
High VEGF expression has been reported to be asso-
ciated with poor prognosis in patients with breast carci-
noma [30], prostate carcinoma [31], melanoma [32,33],
and lung carcinoma [20]. Thus, VEGF is a prognostic
biomarker for NSCLC. On the other hand, lung cancer
risk among subjects administered with TZDs is reduced
by 33% [34] and in vitro studies indicate that TZDs
inhibit the growth of NSCLC cells [27,35]. Purified
VEGF189 and VEGF165 induced cell progression in
human umbilical vascular endothelial cells (HUVEC),
Figure 5 Effect of troglitazone treatment on levels of phosphorylated MAPKs. PC-14 cells were treated with 100 μM troglitazone (TRO) or
vehicle and 24 h after treatment, phosphorylated-MAPK protein levels of ERK1/2, p38, and JNK were measured by western blot analysis.
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231, and the human pancreatic carcinoma cell line
Panc-1 [36]. These reports indicated that one of the
mechanisms as an anti-cancer effect of TZDs was
depressing the VEGF expression.
However, some reports contradict the inductive effect
of TZDs on VEGF [12-19], and this was also observed
in the present study. Our results indicate that the inter-
action of the induced VEGF and NRP-1 may inhibit the
growth of NSCLC cells. Taken together, these results
suggest that rather than being a growth factor for
NSCLC cells, troglitazone-induced VEGF may mediate
cell growth arrest.
It has been recently reported that the mechanism of
VEGF action is complicated [37]. Deletion of myeloid-
cell VEGF-A in multiple subcutaneous isograft models
and in an autochthonous transgenic model of mammary
tumorigenesis resulted in accelerated tumor progression;
this process was accompanied by less overall tumor cell
death and decreased tumor hypoxia. Administration of
TZD to a lung cancer patient induces VEGF expression
and prevents the maturation of the surrounding blood
vessels, thereby leading to tumor suppression by hypoxia
and lack of nutrition. Further, in this study, we showed
that TZD-induced VEGF expression inhibited the growth
of tumor cells. We think that both these effects prolong
the survival of the lung cancer patients. On the basis of
these results, TZD can be used as an effective anti-cancer
agent for the treatment of lung or other cancer patients
with high VEGF expression receptivity toward TZD.
Conclusions
In the present study, we report the existence of a new
pathway for arresting cell growth that involves the inter-
action of troglitazone-induced VEGF and NRP-1 in
NSCLC cells. This suggests that TZDs may be effective
anti-cancer agents, and it may be possible to develop a
new anti-cancer therapy if the mechanisms underlying
these anti-cancer effects are better understood.
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